Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

1991 ◽  
Vol 34 (2) ◽  
pp. 195-196
Author(s):  
RC Young ◽  
LA Walton ◽  
SS Ellenberg ◽  
HD Homesley ◽  
GD Wilbanks ◽  
...  
1991 ◽  
Vol 46 (2) ◽  
pp. 111-113
Author(s):  
ROBERT C. YOUNG ◽  
LESLIE A. WALTON ◽  
SUSAN S. ELLENBERG ◽  
HOWARD D. HOMESLEY ◽  
GEORGE D. WILBANKS ◽  
...  

1990 ◽  
Vol 322 (15) ◽  
pp. 1021-1027 ◽  
Author(s):  
Robert C. Young ◽  
Leslie A. Walton ◽  
Susan S. Ellenberg ◽  
Howard D. Homesley ◽  
George D. Wilbanks ◽  
...  

1993 ◽  
Vol 3 (4) ◽  
pp. 211-218 ◽  
Author(s):  
K. Bertelsen ◽  
B. HØLund ◽  
J. E. Andersen ◽  
K. Nielsen ◽  
I. StrØYer ◽  
...  

Four hundred and ten patients with epithelial ovarian cancer FIGO stages I and II were registered by a Danish multicenter study group (The Danish Ovarian Cancer Group - DACOVA). Two-thirds were stage I, the most frequent substage was Iai which was the classification in 27%. Five-year survival for stage I was 72%, and 38% for stage II. Multivariate analysis showed that age, stage, residual tumor, histologic grade and adjuvant treatment had prognostic value. For stage, three significantly different groups could be identified: (1) stage Iai, (2) stage Iaii-Ic, and (3) stage II. Histologic grade showed a significant survival difference between all grades. Adjuvant treatment had a moderate but significant impact on survival. Patients in stage Iai had a good survival with surgery alone and will probably not benefit from adjuvant therapy. Adjuvant treatment improved survival for the remaining patients in stages I and II without residual tumor. A difference between treatment modalities was not observed. However, the data need to be confirmed by a randomized trial. Patients in stage II with residual tumor should be treated as stage III.


1995 ◽  
Vol 50 (1) ◽  
pp. 28-30
Author(s):  
E. Sartori ◽  
N. Palai ◽  
B. La Face ◽  
S. Pecorelli ◽  
U. A. Bianchi

Cancer ◽  
1989 ◽  
Vol 63 (6) ◽  
pp. 1070-1073 ◽  
Author(s):  
Holly H. Gallion ◽  
John R. van Nagell ◽  
Elvis S. Donaldson ◽  
Robert V. Higgins ◽  
Deborah E. Powell ◽  
...  

2018 ◽  
Vol 38 (11) ◽  
pp. 6507-6511 ◽  
Author(s):  
EDGAR PETRU ◽  
CAROLA HUBER ◽  
EVA SAMPL ◽  
JOSEF HAAS

Cells ◽  
2019 ◽  
Vol 8 (12) ◽  
pp. 1554
Author(s):  
Enrica Calura ◽  
Matteo Ciciani ◽  
Andrea Sambugaro ◽  
Lara Paracchini ◽  
Giuseppe Benvenuto ◽  
...  

Stage I epithelial ovarian cancer (EOC) represents about 10% of all EOCs. It is characterized by a complex histopathological and molecular heterogeneity, and it is composed of five main histological subtypes (mucinous, endometrioid, clear cell and high, and low grade serous), which have peculiar genetic, molecular, and clinical characteristics. As it occurs less frequently than advanced-stage EOC, its molecular features have not been thoroughly investigated. In this study, using in silico approaches and gene expression data, on a multicentric cohort composed of 208 snap-frozen tumor biopsies, we explored the subtype-specific molecular alterations that regulate tumor aggressiveness in stage I EOC. We found that single genes rather than pathways are responsible for histotype specificities and that a cAMP-PKA-CREB1 signaling axis seems to play a central role in histotype differentiation. Moreover, our results indicate that immune response seems to be, at least in part, involved in histotype differences, as a higher immune-reactive behavior of serous and mucinous samples was observed with respect to other histotypes.


2019 ◽  
Vol 134 (5) ◽  
pp. 1017-1026 ◽  
Author(s):  
Koji Matsuo ◽  
Hiroko Machida ◽  
Wataru Yamagami ◽  
Yasuhiko Ebina ◽  
Yoichi Kobayashi ◽  
...  

2017 ◽  
Vol 72 (12) ◽  
pp. 713-715
Author(s):  
Alexander Melamed ◽  
Anthony E. Rizzo ◽  
Roni Nitecki ◽  
Allison A. Gockley ◽  
Amy J. Bregar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document